Description
This episode takes a global health perspective to look at different barriers to the elimination of hepatitis C, in Europe and globally. Diagnosing HCV is one of the key challenges to elimination – how does political will and infrastructure factor into this? What can be done at the EU level to address these barriers? What major challenges do low and middle-income countries face with respect to hepatitis C diagnosis?
The EASL Policy Dialogues are supported by CymaBay, Echosens, Grifols and Novo Nordisk. CymaBay, Echosens, Grifols and Novo Nordisk have had no input into the content of the EASL Policy Dialogues.